Following the activation of NLRP3 in melanoma cells, PMN-MDSCs proliferate in response to IL-1β-induced melanoma-associated inflammation, which results in reduced natural killer and CD8 + T cell activity and enhanced Treg cell population in primary tumors. Here, IL1B is linked to melanoma.